Biohaven strikes $795M deal for commercial partner in epilepsy

South Korea-based SK Biopharmaceuticals has offered up to $795 million for the global rights to Biohaven’s Kv7 ion channel platform, including its lead candidate opakalim. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene…

Source: Endpoints News